Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France.
+ 2 more risks
Adequate balance sheet with limited growth.
Share Price & News
How has Genomic Vision Société Anonyme's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: G09's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: G09 exceeded the German Biotechs industry which returned 5.5% over the past year.
Return vs Market: G09 exceeded the German Market which returned 8.3% over the past year.
Price Volatility Vs. Market
How volatile is Genomic Vision Société Anonyme's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Genomic Vision Société Anonyme undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate G09's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate G09's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: G09 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: G09 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate G09's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: G09 is good value based on its PB Ratio (2.3x) compared to the DE Biotechs industry average (3.5x).
How is Genomic Vision Société Anonyme forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: G09 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: G09 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: G09 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: G09's revenue (99.9% per year) is forecast to grow faster than the German market (5.1% per year).
High Growth Revenue: G09's revenue (99.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if G09's Return on Equity is forecast to be high in 3 years time
How has Genomic Vision Société Anonyme performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: G09 is currently unprofitable.
Growing Profit Margin: G09 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: G09 is unprofitable, and losses have increased over the past 5 years at a rate of -21.5% per year.
Accelerating Growth: Unable to compare G09's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: G09 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: G09 has a negative Return on Equity (-170.89%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Genomic Vision Société Anonyme's financial position?
Financial Position Analysis
Short Term Liabilities: G09's short term assets (€5.0M) exceed its short term liabilities (€2.3M).
Long Term Liabilities: G09's short term assets (€5.0M) exceed its long term liabilities (€617.0K).
Debt to Equity History and Analysis
Debt Level: G09 is debt free.
Reducing Debt: G09 has no debt compared to 5 years ago when its debt to equity ratio was 3%.
Inventory Level: G09 has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if G09's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: G09 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: G09 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -14.6% each year
What is Genomic Vision Société Anonyme's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate G09's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate G09's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if G09's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if G09's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of G09's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Aaron Bensimon 0
Mr. Aaron Bensimon, Ph.D., Co-Founded Genomic Vision, S.A in 2004 and also has been its Chief Executive Officer and president since May 2006. Mr. Bensimon serves as the Scientific Director at Genomic Visio ...
CEO Compensation Analysis
Compensation vs Market: Aaron's total compensation ($USD0.00) is below average for companies of similar size in the German market ($USD414.81K).
Compensation vs Earnings: Aaron's compensation has been consistent with company performance over the past year.
|COO & Member of Management Board||1.1yrs||€205.00k||no data|
|Co-Founder & President of Scientific Advisory Board||0yrs||no data||no data|
|Chief Financial Officer||0.08yrs||no data||no data|
Experienced Management: G09's management team is seasoned and experienced (7.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 165.7%.
Genomic Vision Société Anonyme's company bio, employee growth, exchange listings and data sources
- Name: Genomic Vision Société Anonyme
- Ticker: G09
- Exchange: DB
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €16.941m
- Shares outstanding: 41.27m
- Website: https://www.genomicvision.com
Number of Employees
- Genomic Vision Société Anonyme
- Green Square Batiment E
- 80-84 rue des Meuniers
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GV||ENXTPA (Euronext Paris)||Yes||Common Shares||FR||EUR||Apr 2014|
|G09||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Apr 2014|
|0QT4||LSE (London Stock Exchange)||Yes||Common Shares||GB||EUR||Apr 2014|
|GVP||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Shares||GB||EUR||Apr 2014|
Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. It offers molecular combing system (MCS), an automated instrument that stretches single DNA molecules onto vinyl silane treated glass carriers; FiberVision, an automated fluorescence microscope for high-throughput image acquisition; software solutions for the detection, measurement, and interpretation of hybridization signals on combed DNA in a streamlined and informatics process; DNA extraction kits for molecular combing applications; and accessories, such as custom treated glass carriers and disposable DNA reservoirs for use with the MCS, as well as sample cartridges for scanners. The company also provides CombHeliX FSHD probes for the diagnosis of facioscapulohumeral dystrophy; FiberProbes for BRCA that is a set of Genomic Morse Codes for the detection of mutations occurring in hereditary breast and ovarian cancer; and hereditary nonpolyposis colorectal cancer Genomic Morse Code sets, which allows the identification and characterization of various structural variations, including anomalies occurring in flanking regions of the MMR genes. In addition, it offers combing services that allow customers to validate the planned gene editing events; detect incorrect events larger than 1kb, including incorrect deletions, insertions, or inversions; and quantify off-target/on-target ratios. The company has a strategic alliance with Quest Diagnostics; research and development agreement with the Pasteur Institute and Sanofi; and development agreement with Integrated Technologies Ltd for the design and development of a high-throughput scanning instrument for molecular combing assays. Genomic Vision Société Anonyme was founded in 2004 and is headquartered in Bagneux, France.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/24 23:10|
|End of Day Share Price||2020/02/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.